Eberhard Standl

20.9k total citations · 3 hit papers
210 papers, 9.2k citations indexed

About

Eberhard Standl is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Eberhard Standl has authored 210 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Endocrinology, Diabetes and Metabolism, 53 papers in Cardiology and Cardiovascular Medicine and 41 papers in Surgery. Recurrent topics in Eberhard Standl's work include Diabetes Treatment and Management (82 papers), Diabetes Management and Research (64 papers) and Metabolism, Diabetes, and Cancer (35 papers). Eberhard Standl is often cited by papers focused on Diabetes Treatment and Management (82 papers), Diabetes Management and Research (64 papers) and Metabolism, Diabetes, and Cancer (35 papers). Eberhard Standl collaborates with scholars based in Germany, Italy and United States. Eberhard Standl's co-authors include Oliver Schnell, Lars Rydén, Antonio Ceriello, Darren K. McGuire, Rury R. Holman, Eric D. Peterson, Jennifer B. Green, John B. Buse, Paul W. Armstrong and John M. Lachin and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Eberhard Standl

202 papers receiving 8.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015 1.9k citations Jennifer B. Green, M. Angelyn Bethel et al. profile →
Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications

2019 584 citations Antonio Ceriello, Oliver Schnell et al. European Journal of Preventive Cardiology profile →
The global epidemics of diabetes in the 21st century: Current situation and perspectives

2019 309 citations Eberhard Standl, Kamlesh Khunti et al. European Journal of Preventive Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eberhard Standl Germany	47	6.0k	2.4k	2.1k	2.1k	884	210	9.2k
Paola Fioretto Italy	53	4.1k 0.7×	2.0k 0.9×	1.9k 0.9×	1.9k 0.9×	859 1.0×	201	10.2k
Zachary T. Bloomgarden United States	44	5.9k 1.0×	2.2k 0.9×	2.1k 1.0×	1.3k 0.6×	892 1.0×	264	9.5k
Jorge Luiz Gross Brazil	51	5.8k 1.0×	2.3k 0.9×	2.3k 1.1×	1.4k 0.7×	659 0.7×	234	10.5k
B Charbonnel France	46	7.1k 1.2×	2.8k 1.2×	3.3k 1.6×	1.2k 0.6×	756 0.9×	240	9.7k
George Jerums Australia	66	4.6k 0.8×	1.3k 0.5×	2.1k 1.0×	2.7k 1.3×	844 1.0×	285	13.4k
Russell Scott New Zealand	45	5.9k 1.0×	4.8k 2.0×	2.7k 1.3×	1.9k 0.9×	620 0.7×	235	11.4k
Giancarlo Viberti United Kingdom	62	6.6k 1.1×	2.1k 0.9×	3.7k 1.8×	3.8k 1.8×	1.0k 1.1×	190	13.7k
Sanjoy K. Paul Australia	30	7.9k 1.3×	2.0k 0.8×	2.5k 1.2×	1.4k 0.7×	877 1.0×	106	10.7k
Saul Genuth United States	43	7.3k 1.2×	2.2k 0.9×	2.3k 1.1×	2.2k 1.1×	1.3k 1.4×	112	11.9k
Byron J. Hoogwerf United States	46	4.6k 0.8×	2.2k 0.9×	1.6k 0.8×	1.6k 0.8×	402 0.5×	142	8.1k

Countries citing papers authored by Eberhard Standl

Since Specialization

Citations

This map shows the geographic impact of Eberhard Standl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eberhard Standl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eberhard Standl more than expected).

Fields of papers citing papers by Eberhard Standl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eberhard Standl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eberhard Standl. The network helps show where Eberhard Standl may publish in the future.

Co-authorship network of co-authors of Eberhard Standl

This figure shows the co-authorship network connecting the top 25 collaborators of Eberhard Standl. A scholar is included among the top collaborators of Eberhard Standl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eberhard Standl. Eberhard Standl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Standl, Eberhard & Oliver Schnell. (2025). Increased Risk of Cancer—An Integral Component of the Cardio–Renal–Metabolic Disease Cluster and Its Management. Cells. 14(8). 564–564.

Marx, Nikolaus, Lars Rydén, Massimo Federici, et al.. (2024). Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction. European Heart Journal. 45(48). 5117–5126. 4 indexed citations

Regan, Jessica A., Robert J. Mentz, Jennifer B. Green, et al.. (2023). Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. JCI Insight. 8(17). 9 indexed citations

Ibrahim, Mahmoud, Avivit Cahn, Robert H. Eckel, et al.. (2020). Hypoglycaemia and its management in primary care setting. Diabetes/Metabolism Research and Reviews. 36(8). e3332–e3332. 12 indexed citations

Ceriello, Antonio, Eberhard Standl, Doina Catrinoiu, et al.. (2020). Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era. Diabetes Care. 43(7). 1427–1432. 57 indexed citations

Marx, Nikolaus, Lars Rydén, Frank C. Brosius, et al.. (2020). Proceedings of the Guideline Workshop 2019: Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases, and Kidney Diseases. Diabetes Technology & Therapeutics. 22(7). 546–552. 2 indexed citations

Standl, Eberhard, Susanna R. Stevens, Yuliya Lokhnygina, et al.. (2019). Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care. 43(3). 643–652. 36 indexed citations

Standl, Eberhard, Kamlesh Khunti, Tina Birgitte Hansen, & Oliver Schnell. (2019). The global epidemics of diabetes in the 21st century: Current situation and perspectives. European Journal of Preventive Cardiology. 26(2_suppl). 7–14. 309 indexed citations breakdown →

Standl, Eberhard, Susanna R. Stevens, Paul W. Armstrong, et al.. (2018). Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care. 41(3). 596–603. 49 indexed citations

10.

Davis, Timothy M. E., Hillary Mulder, Yuliya Lokhnygina, et al.. (2018). Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obesity and Metabolism. 20(6). 1427–1434. 23 indexed citations

11.

Standl, Eberhard. (2018). Heart failure in diabetes: From an increased risk to a treatment target. Diabetes Mellitus. 21(5). 399–403. 2 indexed citations

12.

Sharma, Abhinav, Jennifer B. Green, Allison Dunning, et al.. (2017). Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care. 40(12). 1763–1770. 53 indexed citations

13.

Bethel, M. Angelyn, S. Engel, Eberhard Standl, et al.. (2016). Assessing the safety of sitagliptin in elderly participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetic Medicine. 33. 86–86. 1 indexed citations

14.

Preiss, David, Laine Thomas, Jie‐Lena Sun, et al.. (2012). Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open. 2(6). e001925–e001925. 41 indexed citations

15.

Eckert, Siegfried, Erland Erdmann, W. A. Scherbaum, et al.. (2007). Positionsbestimmung zum Stellenwert von Pioglitazon in der Diabetestherapie. DMW - Deutsche Medizinische Wochenschrift. 132(49). 2650–2653.

16.

Standl, Eberhard. (2002). International Diabetes Federation European Policy Group Standards for Diabetes. Endocrine Practice. 8. 37–40. 10 indexed citations

17.

Schnell, Oliver, Daniela Muhr, Carl‐Martin Kirsch, et al.. (1997). Three-year follow-up on scintigraphically assessed cardiac sympathetic denervation in patients with long-term insulin-dependent (type I) diabetes mellitus. Journal of Diabetes and its Complications. 11(5). 307–313. 15 indexed citations

18.

Ziegler, Anette G., et al.. (1997). Alström-Syndrom — eine seltene Erkrankung aus dem diabetischen Formenkreis. Medizinische Klinik. 92(3). 175–178. 3 indexed citations

19.

Schnell, Oliver, et al.. (1995). Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Diabetologia. 38(11). 1345–1352. 57 indexed citations

20.

Standl, Eberhard, et al.. (1976). Muscle metabolism during rest and exercise: influence on the oxygen transport system of blood in normal and diabetic subjects.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 25(2 SUPPL). 914–9. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact